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Homeostatic scaling adjusts the strength of synaptic
connections up or down in response to large
changes in input. To identify the landscape of prote-
omic changes that contribute to opposing forms of
homeostatic plasticity, we examined the plasticity-
induced changes in the newly synthesized prote-
ome. Cultured rat hippocampal neurons underwent
homeostatic up-scaling or down-scaling. We used
BONCAT (bio-orthogonal non-canonical amino acid
tagging) to metabolically label, capture, and identify
newly synthesized proteins, detecting and analyzing
5,940 newly synthesized proteins using mass spec-
trometry and label-free quantitation. Neither up- nor
down-scaling produced changes in the number of
different proteins translated. Rather, up- and down-
scaling elicited opposing translational regulation
of several molecular pathways, producing targeted
adjustments in the proteome. We discovered 300
differentially regulated proteins involved in neurite
outgrowth, axon guidance, filopodia assembly,
excitatory synapses, and glutamate receptor com-
plexes. We also identified differentially regulated
proteins that are associated with multiple diseases,
including schizophrenia, epilepsy, and Parkinson’s
disease.
INTRODUCTION
Neuronal networks are subject to fluctuations in both the magni-
tude and frequency of inputs, requiring plasticity mechanisms to
stabilize network activity. Homeostatic synaptic scaling adjusts
the strength of neuronal connections up or down in response
to changes in input (Davis, 2013; Turrigiano, 2012). At the
Drosophila neuromuscular junction, genetic manipulations that
alter postsynaptic receptor function result in compensatory
changes in presynaptic neurotransmitter release (see Davis,
2013 for review). At mammalian synapses, blocking action
potential-mediated activity either pharmacologically (O’Brien358 Neuron 92, 358–371, October 19, 2016 ª 2016 The Author(s). Pu
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(Desai et al., 2002) or by suppressing excitability (Burrone
et al., 2002) can lead to a global up-scaling of synaptic re-
sponses. Conversely, a global stimulation of activity, effected
by blocking GABAA receptor-mediated inhibition, leads to a
significant down-scaling of synaptic responses (O’Brien et al.,
1998; Turrigiano et al., 1998).
What is the nature of the molecular changes that bring about
the synaptic scaling at mammalian synapses? Several groups
have postulated that fluctuations in intracellular Ca2+ levels
initially ‘‘sense’’ changes in activity (Ibata et al., 2008; Thiagarajan
et al., 2005) that may be read out by changes in the activation of
CaMKIV resulting in changes in gene expression (Ibata et al.,
2008). In addition, the expression of scaling up is mediated by
the accumulation of GluR2-containing receptors (Gainey et al.,
2009, 2015), likely driven by alterations with the glutamate recep-
tor-interacting protein-1, GRIP-1 (Gainey et al., 2015), and
protein-interacting-with C Kinase 1, PICK1 (Anggono et al.,
2011). Other molecules implicated in various aspects of synaptic
scaling include the neurotrophin brain-derived neurotrophic fac-
tor (BDNF) (Rutherford et al., 1998), the immediate early gene Arc
(Shepherd et al., 2006), the cytokine TNFa (Steinmetz and Turri-
giano, 2010; Stellwagen and Malenka, 2006), the immune mole-
cule MHC1 (Goddard et al., 2007), b3 integrins (Cingolani et al.,
2008), and the scaffold proteins PSD-95 and PSD-93 (Sun and
Turrigiano, 2011). All of the abovemoleculeswere discovered us-
ing a candidate-based approach, making good ‘‘guesses’’ about
the players that might be important, leaving open the possibility
that many important molecules have not yet been discovered.
The long time course (24 hr) required for most forms of syn-
aptic homeostasis to be established (O’Brien et al., 1998; Turri-
giano et al., 1998) suggests a requirement for changes in gene
expression, either by regulated transcription or translation, or
both. Indeed, upscaling elicited by a 24 hr TTX treatment is
blocked by a transcription inhibitor (Ibata et al., 2008). In a
form of homeostatic depression elicited by ChR2-stimulation
of individual neurons, a requirement for both transcription and
translation has been reported (Goold and Nicoll, 2010). Whether
the classic homeostatic plasticity, elicited pharmacologically,
requires changes in new protein translation has, surprisingly,
not been addressed.
What is known about the transcriptomic and proteomic alter-
ations that underlie homeostatic plasticity? A recent studyblished by Elsevier Inc.
commons.org/licenses/by/4.0/).
studied a few selected transcripts with qPCR and showed that
homeostatic upscaling resulted in a significant increase in the
Gria1, Tet1, and Gadd 45b transcripts (Meadows et al., 2015).
While alterations in transcripts can lead to changes in protein
abundance, several studies have shown that in complex sys-
tems the correlation between the transcriptome and the prote-
ome can be low (Gygi et al., 1999; Komatsu and Hossain,
2013; Jovanovic et al., 2015). As proteins are the primary and
most common effectors in all cellular processes, it is important
to determine the proteome directly to understand how plasticity
fundamentally alters the neuronal and synaptic landscape.
Recent advances in proteomic technology have led to unprec-
edented coverage and depth in the identification of proteins in
cells and tissues. A recent study, for example, identified over
8,000 proteins in each of several different brain areas, including
the hippocampus (Sharma et al., 2015). In addition, over 2,000
proteins reliably associated with the postsynaptic density have
also been identified (Distler et al., 2014; Peng et al., 2004; Pielot
et al., 2012; Cajigas et al., 2012). Quantitative proteomic ana-
lyses that focus on the entire (unlabeled) proteome, however,
do not allow one to identify proteins synthesized in response to
plasticity. For example, if one observes an increase in protein
levels, it is impossible to determine whether the increase is due
to enhanced protein synthesis or decreased protein degrada-
tion. In order to isolate the analysis of the newly synthesized pro-
teome associated with plasticity, metabolic labeling is required.
Bio-orthogonal non-canonical amino acid tagging (BONCAT) en-
ables pulsed metabolic labeling of newly synthesized proteins
using non-canonical amino acids like azidohomoalanine (AHA)
together with click-chemistry followed by mass spectrometry
(Dieterich et al., 2006, 2007). Using this method, alterations in
newly synthesized proteins can be directly determined. This
approach has been applied to identify newly synthesized pro-
teins in many systems (Landgraf et al., 2015), including in the
hippocampus following treatment with dopamine (Hodas et al.,
2012) or BDNF (Bowling et al., 2016).
The opposite phenotypes elicited during synaptic up-scaling
and down-scaling represent a unique opportunity to examine
the underlying proteomic plasticity and identify pathways that
are bi-directionally or coordinately regulated. Here we detect
an unprecedented number of newly synthesized proteins and
provide a comprehensive map of the newly synthesized prote-
ome following both up- and down-scaling.
RESULTS
To ascertain, first, whether pharmacologically elicited synaptic
scaling requires protein synthesis, we conducted experiments
in which protein synthesis was inhibited during the scaling
manipulation (Figure S1). In order to elicit up-scaling, cultured
hippocampal neurons were treated with the Na+ channel antag-
onist tetrodotoxin (1 mM) for 24 hr to elicit an increase inminiature
excitatory postsynaptic current (mEPSC) amplitude (Figure S1A).
The co-application of the protein synthesis inhibitor anisomycin
(40 mM) prevented the mEPSC amplitude increase (Figure S1B).
In order to elicit down-scaling, cultured hippocampal neurons
(DIV 21) were treated with the GABAA receptor antagonist bicu-
culline (40 mM) for 24 hr to elicit a decrease in mEPSC amplitude(Figure S1A). The co-application of the protein synthesis inhibitor
anisomycin (40 mM) prevented the mEPSC amplitude decrease,
indicating a requirement for new protein synthesis (Figure S1C).
Taken together, these data demonstrate that protein synthesis
is required for both up- and down-scaling elicited pharma-
cologically in cultured neurons.
In order to identify the specific proteins synthesized following
global manipulations of neuronal activity, we used BONCAT (Fig-
ures 1 and 2; Dieterich et al., 2006) together with the paradigm of
homeostatic scaling. For the duration of the scaling induction
(24 hr of either bicuculline or TTX, as above) cultured hippocam-
pal neurons (DIV 21) were treated with the non-canonical amino
acid azidohomoalanine (AHA; 4 mM) to label the newly synthe-
sized proteins associated with homeostatic scaling. A control
group was exposed to AHA for 24 hr in the absence of either
bicuculline or TTX. An additional negative control group was
treated with methionine, the amino acid from which AHA is
derived (Met; 4 mM) (Figure 2A). Following scaling induction,
neuronal lysates were prepared and BONCAT (see Experimental
Procedures) was performed to capture, purify, and identify the
newly synthesized proteins (Figure 2A). For each set of experi-
ments, we conducted five independent biological replicates
that were each injected in four technical replicate LC-MS/MS
runs (see Experimental Procedures; Figure 1 and S2). To identify
proteins, we required a minimum of one tryptic peptide per pro-
tein (see Experimental Procedures; Table S9). With a few excep-
tions (see Experimental Procedures), any protein detected in a
methionine control experiment was subtracted from our experi-
mental dataset, and only proteins present in more than two bio-
logical replicates were retained for subsequent analysis.
In the above experiments, we obtained an unprecedented
coverage and depth of the newly synthesized proteome. Our
master dataset, comprising the union of the untreated, scaled-
up, and scaled-down groups, includes 5,940 unique protein
groups representing all key cellular processes, including meta-
bolic enzymes, cell signaling, and structural proteins (Figures 1
and 2B; Table S1). We were able to detect most of the important
neuronal membrane proteins including ion channels and a
majority of the subunits of the excitatory and inhibitory neuro-
transmitter receptors, including AMPA and NMDA receptor
subunits as well as GABAA and GABAB receptors (Figures 5
and S5; Tables S1 and S3). In addition, we identified many
membrane proteins associated with presynaptic membranes
and vesicles, including both vesicular and plasma membrane
transporters (Figure 6; Tables S1 and S3). These data are
described in much greater detail below.
In order to assess the depth and breadth of our newly synthe-
sized proteome, we compared the newly synthesized proteome
of control (not subjected to scaling) AHA-treated neurons to a
global hippocampal proteome dataset (Sharma et al., 2015)
(see Experimental Procedures; Figure 1). We found that there
was substantial overlap between the pulse (24 hr)-labeled
nascent hippocampal proteome and the global hippocampal
proteome (Figure 2C). The AHA-labeled proteome also captured
many proteins not identified in the global proteome, likely owing
to the specific enrichment and reduced sample complexity of
the AHA-proteome and the resulting expanded dynamic range.
We considered the possibility that some of the AHA-exclusiveNeuron 92, 358–371, October 19, 2016 359
Figure 1. Overall Workflow Including Sample Structure, Preparation, Analyses and Data Processing, and Evaluation
Flow chart explaining the datasets used, how the data were filtered, and how we calculated the numbers of proteins in each figure as well as the conversion to
genes, when appropriate.
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Figure 2. Workflow and Characterization of the Newly Synthesized Proteome
(A)Workflow of experiments. Cultured hippocampal neurons (DIV 21) were treatedwith AHA (4mM) and either vehicle, TTX (1 mM), or bicucculine (20 mM) for 24 hr.
Control cultured neurons were exposed tomethionine (4mM) for 24 hr. Neuronswere then harvested, and proteins were solubilized and clicked to alkyne-bearing
beads. An on-resin digestion was performed, and peptides were then identified via liquid chromatography-mass spectrometry (LC-MS/MS). Proteins were
identified and quantified using MaxQuant and other tools (see Experimental Procedures).
(B) Representation of protein groups in different cellular compartments.
(C) Venn diagram of the global hippocampal proteome (identified in Sharma et al., 2015) compared to the newly synthesized proteome (identified by 24 hr of AHA
labeling).
(D) Plot of protein half-lives for the global versus newly synthesized proteomes. Available data from Cohen et al. (2013) for 60 AHA-labeled and global proteome
proteins are shown. There is a trend for shorter half-lives of the AHA-identified proteins.
(E) Graph indicating the number of identified proteins across biological replicates for each group. Homeostatic scaling does not change the size of the nascent
proteome. A significantly smaller number of proteins were identified in the negative control (methionine-treated) group (p < 0.0001), but none of the other groups
differed significantly from one another. Error bars represent ± SEM.
(F) Reproducibility of protein identifications across biological replicates within each group.
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Figure 3. The Synthesis of 300 Proteins Is
Differentially Regulated by Homeostatic
Scaling
(A) Scatterplot indicating every analyzed protein
(n = 4,186). Proteins that were significantly regu-
lated by homeostatic plasticity are indicated as
mauve dots; all other proteins are gray. Histograms
on the horizontal (teal) and vertical (orange) axes
indicate the number of proteins that exhibited a
given fold-change on the x (teal) and y (orange)
axes.
(B) Venn diagram depicting the total number and
low-abundant, newly synthesized proteins identi-
fied in each of the following groups: scaled-up
(TTX-treated), scaled-down (bicuculline-treated),
or untreated (control). Proteins were manually ex-
tracted as outlined in Experimental Procedures.
(C) Functional groups of significantly regulated
proteins observed following up- or down-scaling.proteins represent short-lived proteins that are less likely to be
detected in the large global proteome sample. To examine this
possibility, we compared the reported protein half-lives for the
AHA-exclusive proteins to a comparable number of proteins
from the global hippocampal proteome. Using data from Cohen
et al. (2013), we extracted all of the half-life data for AHA-exclu-
sive proteins analyzed in their dataset (n = 60) and compared the
distribution of half-lives to the same number of proteins sub-
sampled from the global hippocampal proteome. We observed
a shift toward a shorter half-life in the distribution for AHA-
labeled proteins (Figure 2D), suggesting that one feature of the
AHA-exclusive proteins may be a faster turnover, making the
proteins more difficult to capture and detect in global proteomic
studies.
We next analyzed the newly synthesized proteome in control
(untreated), scaled-up, and scaled-down samples. First we
examined the total nascent proteome size and discovered that
homeostatic scaling does not significantly alter the number of
unique newly synthesized proteins in the total proteome. The
total nascent proteome size in each group (control, scaled-up,
and scaled-down) was between 5,100 and 5,200 proteins
(Figures 1 and 2E; Table S1). In the negative control methi-
onine-treated samples, there were 594 proteins detected.
Notably, in each AHA-treated group, over 80% of the proteins362 Neuron 92, 358–371, October 19, 2016ze
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and over90% of the proteins were iden-
tified in 2/5 biological replicates (Fig-
ure 2F). As there was no significant differ-
ence in the newly synthesized proteome
size between groups, these data indicate
that homeostatic scaling is associated
with a balanced stimulation and inhibition
of synthesis of protein groups.
We hypothesized that the dominant
class of proteomic change during scaling
would comprise changes in the abun-
dance of proteins that perform essential
cellular and synaptic functions. To analythis, we compared protein abundances in the up-scaled
down-scaled nascent proteomes to control nascent proteom
using a label-free quantitation (LFQ)-based analysis (see Expe
imental Procedures; Figure 1). Altogether, we discovered ov
300 proteins with significantly regulated expression leve
following homeostatic plasticity (Figures 3A and S4; Table S
This group comprises proteins that are co-regulated or sing
regulated by either up- or down-scaling. Figure 3A depicts
proteins analyzed, and the four quadrants in the graph highlig
four basic categories of significantly regulated newly synth
sized proteins. Two quadrants depict proteins that exhibit coo
dinate regulation: both up- and down-scaling result in either
enhancement (upper right quadrant) or a reduction (lower l
quadrant) in the synthesis of particular proteins.When compar
to control samples, there were 70 proteins that exhibit
enhanced protein synthesis associated with both up-scali
and down-scaling (Figure 3A, upper right quadrant). Som
of the protein families that were overrepresented inclu
the following: transcriptional activation, mRNA transport a
splicing, and tyrosine phosphatases and kinases (Table S
On the other hand, when compared to control samples, the
were 97 proteins that exhibited reduced protein synthesis du
ing both up-scaling and down-scaling (Figure 3A, lower l
quadrant). Functional annotation analysis reveals a significa
Figure 4. Differential Enrichment of Up- and
Down-scaled Nascent Proteins
Selected significantly regulated protein groups
or pathways that exhibit opposite or differential
regulation by up- and down-scaling (teal and or-
ange bars, respectively). FDR = false discovery
rate.enrichment of protein families mediating inositol-1,4,5-triphos-
phate-sensitive calcium release, sphingomyelin degradation,
and cell-cell adhesion essential for dendritic spine morphogen-
esis as well as other cellular functions (Table S3). Taken together,
these two groups of proteins exhibit consistent enhanced or
reduced synthesis, regardless of the sign of the plasticity, and
thus might be considered as ‘‘general’’ scaling proteins that
respond to global changes in neuronal activity.
The remaining categories are represented by proteins signifi-
cantly altered in a bi-directional manner: for these proteins,
enhanced synthesis is associated with one form of plasticity
(either up- or down-scaling) while reduced synthesis is associ-
ated with the other form (Figures 3A and 4; Table S2). When
compared to control samples, there were 105 proteins that ex-
hibited enhanced protein synthesis associated with up-scaling
and reduced protein synthesis during down-scaling (Figure 3A,
lower right quadrant). GO analysis of this group indicates a
significant enrichment for proteins largely involved in synaptic
function, including, for example, the family of Ca2+-calmodulin-
dependent protein kinases (CamK) and proteins involved in
neurotransmitter transport and exocytosis (Figure 4; Table S3).
Indeed, the most differentially regulated group was the iono-
tropic glutamate receptor complex, the target of many mecha-
nistic studies of homeostasis (Table S5) (Turrigiano, 2012).
When compared to control samples, there were 35 proteins
that exhibited enhanced protein synthesis during down-scaling
and reduced protein synthesis during up-scaling (Figure 3A, up-
per left quadrant; Figure 4). Functional annotation analysis of this
group indicates a significant enrichment of calcium-dependent
protein serine/threonine phosphatases, splicing factors, tran-
scription factors, calcineurin regulators, and synaptotagmins.
Additional enriched proteins in this group are implicated in
mRNA deadenylation, ubiquitin activation, cell growth, and other
categories (Table S3). The above proteins should thus be consid-
ered as ‘‘specific’’ scaling proteins that respond with a specific
signature to either homeostatic up- or down-scaling.
We also considered the entire population (307) of regulated
nascent proteins as a single group and examined, using a Stringth
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GrNanalysis, the networks of regulated
proteins and the interactions between
them (Figure S3). We identified one large
network of regulated proteins containing
95 network members with the number
of interaction partners ranging from 1
to greater than 7. Protein hubs in this
networkwere represented by several pro-
tein kinases including the Fyn kinase, Lyn
kinase, Map kinase 3, and Protein kinase
C beta. In addition, other proteins such ase FGF receptor were linked to several other significantly regu-
ed proteins. The remaining networks comprising significantly
gulated proteins were small, ranging from 2 to 6 proteins,
d the remaining regulated proteins were not linked to
tworks.
Finally, we considered the possibility that elements of the
meostatic proteomic response could be newly synthesized
oteins that were uniquely and exclusively associated with
her the control or scaled groups.We found no highly abundant
10 peptides) proteins exclusively in scaled-up or scaled-down
urons. As regulatory proteins may be low abundant or only
ld a low number of detectable peptides, we manually in-
ected low-abundance proteins in our dataset based on repro-
cibility, spectral counting, and normalized peptide intensity
tios (for a detailed description, see Experimental Procedures).
knowledging that this approach yields only trends rather than
ecise quantitative values, we identified 27 and 7 proteins with
her abundance in scaled-up neurons or scaled-down neu-
ns, respectively (Figures 1 and 3B; Tables S1 and S2). Using
ese ‘‘relaxed’’ criteria, newly synthesized proteins enriched in
aled-up neurons were implicated in glutamatergic synapses
d excitability (Adcy2, Grin2a), calcium transport (Atp2b3),
rve growth factor signaling (Lmtk2), and other cellular func-
ns (Table S2). The newly synthesized proteins enriched in
aled-down neurons included proteins involved in synapse
rmation (Arhgap) and modulation of dendritic spines (Dgkz)
able S2). An additional six proteins were found to be enriched
both scaled groups (Table S2), including proteins involved
modulation of dendritic spine shape (Synpo), regulation of
e number of excitatory synapses (C1ql3), and axonal branch-
(Fgf2).
We next determined the changes that occurred in different cell
pes, compartments, and signaling pathways. Within the post-
naptic compartment (Figure 5; Table S4), we found several
amples where the opposite phenotypic endpoints of homeo-
atic scaling are associated with opposing effects on glutamate
ceptors. For example, some subunits of AMPA-type (Gria3,
id1) and a kainate-type (Grik2) receptor showed a pattern ofeuron 92, 358–371, October 19, 2016 363
Figure 5. Proteins Associated with Postsynaptic Function at Excitatory Synapses that Are Regulated by Homeostatic Scaling
The glutamatergic synapse. Proteins in white or gray boxes were detected in this study. Call-out boxes display intensity values (see Experimental Procedures).
The bars, teal and ochre, represent the regulation of the protein in up- and down-scaling, respectively. Asterisks within the colored bar indicate that the protein
exhibited significant (ANOVA FDR < 0.05 and Fisher LSD post hoc p < 0.05) regulation relative to control; asterisks associated with the black lines indicate the
protein exhibited significant (ANOVA FDR < 0.05 and Fisher LSD post hoc p < 0.05) regulation between up- and down-scaling.upregulation during scaling-up accompanied in some cases
(Grid1, Grik2) by downregulation during scaling-down, as ex-
pected if the receptors are modulated to increase or decrease
sensitivity to neurotransmitter (Figure 5; Table S4). (Unfortu-
nately, we did not obtain a sufficient number of unique peptides
for Gria1 and 2 to conduct an analysis.) The NMDA receptor sub-
unit Grin2b exhibited a trend for downregulated synthesis in both
up- and down-scaling, although to a much greater extent during
down-scaling (Figure 5). Other postsynaptic components that
underwent regulation include Cript (Niethammer et al., 1998)
and Lrcc7 (Densin-180). Map kinase 3 (Mapk3), a kinase impli-
cated in long-term potentiation (LTP; Mazzucchelli et al., 2002)
and implicated in autism spectrum disorders (Kumar et al.,
2008), was significantly differentially regulated: enhanced in
scaled-up conditions and reduced in scaled-down conditions
(Tables S2 and S4). Several adhesion molecules, Tnr, Cadh11,
Pcdhgc3, and Sema6d, were also significantly regulated with a
clear trend for downregulation in both forms of scaling (Figure 5;
Tables S2 and S4), reminiscent of earlier studies showing that
downregulation of adhesion is required for structural plasticity
at synapses (Mayford et al., 1992; Schuster et al., 1996).
Nlgn2, in contrast, was significantly upregulated by homeostatic
up-scaling (Figure 5; Tables S2 and S4).
Within the functional area of vesicular trafficking and neuro-
transmitter release, we observed many significantly regulated
proteins (Figure 6; Table S4). Some vesicle-associated proteins364 Neuron 92, 358–371, October 19, 2016like members of the syntaxin family (Syt6 and Esyt1) exhibited
enhanced synthesis following down-scaling, whereas Snap29,
a protein involved in multiple membrane trafficking steps, and
Brsk1, a protein implicated in neurotransmitter release, were
significantly differentially regulated by homeostatic scaling and
reduced following down-scaling (Figures 4 and 6). Some pro-
teins in the Ap-3 family (Ap3b2 and Ap3m2), a heterotetrameric
vesicle-coat protein complex that is important for protein sorting
and clathrin recruitment, exhibited significantly different expres-
sion with up- and down-scaling and were significantly upregu-
lated with up-scaling (Figures 4 and 6; Tables S2 and S4).
Related to the actin cytoskeleton, several proteins (Evl, Sptbn4,
and Vasp) showed extremely robust and significant regulation
consistently with down-scaling, but also with up-scaling (Fig-
ure 6; Tables S2 and S4).
As homeostatic plasticity is known to involve regulation
of inhibitory transmission (Hartman et al., 2006; Kilman et al.,
2002; Maffei et al., 2004), we next examined the protein compo-
nents of GABAergic synaptic transmission that exhibit altered
protein synthesis (Figure S5). The family of GABAA receptors
was significantly regulated and exhibited, in general, opposite
changes for up- and down-scaling (Figure S5). The GABA recep-
tor scaffolding molecule Gephyrin showed a similar trend
(Figure S5). Neuroligin 2 (Nlgn2), a protein implicated in the clus-
tering of GABA receptors, and Kirrel3, a protein implicated
in GABAergic synapse formation, both exhibited significant
Figure 6. Proteins Associated with Presynaptic Function which Are Regulated by Homeostatic Scaling
The presynaptic terminal. Proteins in white or gray boxes were detected in our samples; call-out boxes display intensity values (see Experimental Procedures).
The bars, teal and ochre, represent the regulation of the protein in up- and down-scaling, respectively. Asterisks within the colored bar indicate that the protein
exhibited significant (ANOVA FDR < 0.05 and Fisher LSD post hoc p < 0.05) regulation relative to control; asterisks associated with the black lines indicate the
protein exhibited significant (ANOVA FDR < 0.05 and Fisher LSD post hoc p < 0.05) regulation between up- and down-scaling.upregulation following up-scaling (Figure S5). Synthesis of the
vesicular GABA transporter, Slc32a1, was reduced in down-
scaled neurons and slightly enhanced in up-scaled neurons
(Figure S5). Interestingly, Kif5a, a microtubule-dependent motor
essential for the transport of GABAA receptors (Nakajima et al.,
2012) was significantly differentially regulated and upregulated
in scaled-up neurons (Figure S5).
Since AHA-labeled newly synthesized proteins can originate
from either the glial or neuronal cells present in our hippocampalcultures, we used bioinformatics (GeneAnalytics; see Experi-
mental Procedures) to separately analyze the proteins associ-
ated with glial function. For the 5,940 proteins in the global
AHA-labeled proteome, there are 6,339 associated genes; of
these, 929 genes (14.7%) are associated with glial function
(Table S6). For the 307 significantly regulated proteins in the
AHA-proteome, there are 325 associated genes; of these, 41
genes (12.6%) are associated with glial function (Table S6). It is
important to note that the GeneAnalytics tool we used identifiesNeuron 92, 358–371, October 19, 2016 365
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Figure 7. Ca2+ Signaling Pathway Proteins that Are Regulated by Homeostatic Scaling
Intracellular signaling pathways. Proteins in white or gray boxes were detected in our samples; call-out boxes display intensity values (see Experimental
Procedures). The bars, teal and ochre, represent the regulation of the protein in up- and down-scaling, respectively. Asterisks within the colored bar indicate that
the protein exhibited significant (ANOVA FDR < 0.05 and Fisher LSD post hoc p < 0.05) regulation relative to control; asterisks associated with the black lines
indicate the protein exhibited significant (ANOVA FDR < 0.05 and Fisher LSD post hoc p < 0.05) regulation between up- and down-scaling.glial-associated genes, but does not identify glial-exclusive
genes. As such, some of the regulated genes are shared with
neurons, and the cell type where the protein is significantly
altered—glia, neurons, or both—is not certain. Cell-type-specific
labeling techniques (see Discussion) will certainly be useful to
address this issue in the future.
As Ca2+-regulated and synapse-to-nucleus signaling play a
prominent role in all forms of plasticity, including homeostatic
plasticity, we also searched for altered protein synthesis in
these pathways (Figure 7; Table S4). The CamKII family of sub-
units, for example, showed a consistent trend of upregulated
synthesis following scaling-up and downregulated synthesis
following scaling-down (Figure 7; Table S2). A similar pattern366 Neuron 92, 358–371, October 19, 2016was observed for the beta subunit of Protein kinase C (Prkcb)
and several of the Map kinases (Mapk3, Map4k, and Mapk8)
(Figure 7). The inositol trisphosphate receptor 2 (ITPR2) was
also potently and significantly downregulated with both forms
of plasticity, whereas the ITPR1 molecule was significantly
downregulated exclusively with scaling-up (Figure 7). The family
of Arhgaps, negative regulators of Rho GTPases, together with
the positive regulator of Rho GTPases and dendritic morphology
regulator Tiam1 (Um et al., 2014), represent a hotspot for signif-
icant regulation during homeostatic scaling.
In the above sections, we highlighted some proteins that
are altered during synaptic scaling. As defects in synaptic
scaling have been proposed to contribute to diseases such as
Figure 8. Neurological Disease-Associated Proteins Regulated by Homeostatic Scaling
Shown are genes of significantly regulated proteins associated with each of the indicated diseases. Of the 325 genes regulated by scaling induction, 166 are
associated with one of the diseases shown. Some genes are listed for multiple diseases.Alzheimer’s disease (Pratt et al., 2011) and epilepsy (Trasande
and Ramirez, 2007), we asked whether any of the regulated pro-
teins identified in this study are associated with neurodevelop-
mental, psychiatric, or neurodegenerative disorders. Forty-five
percent of the proteins regulated during homeostatic scaling
had an association with a neural disease. As shown in Figure 8,
we queried regulated proteins associated with Alzheimer’s dis-
ease, Parkinson’s disease, Huntington’s disease, schizophrenia,
epilepsy, autism, amyotrophic lateral sclerosis, multiple scle-
rosis, bipolar disorder, depression, and frontotemporal dementia
(see also Table S7) and found over 166 proteins that were asso-
ciated with at least one of the above diseases. Within this set
of disease-related regulated proteins, we identified that, for
example, Presenilin-1 (Psen), previously reported to be essential
for homeostatic scaling (Pratt et al., 2011), is significantly regu-
lated in both up- and down-scaling (Figures 6 and 8; Table S2).
We additionally examined the association of our regulated
proteins with disease-related single-nucleotide polymorphisms
identified in genome-wide association studies (GWAS) (Table
S7). Here we again found that a large number (95) of the
proteins regulated by synaptic homeostasis are associated
with neurological dysfunction.
DISCUSSION
In this study, we examined the proteomic changes that under-
lie homeostatic scaling in primary hippocampal neurons. We
demonstrate for the first time that both up- and down-scaling
elicited by pharmacological manipulation of neuronal activity
require new protein synthesis. Using BONCAT (Dieterich et al.,
2006), we selectively labeled, purified, and analyzed the newly
synthesized neuronal proteomes. Here, BONCAT enabled usto track and visualize proteome adaptations during homeostatic
scaling that are usually extremely challenging to examine in tis-
sue samples due to both the dynamic range of the proteome
and the relatively small degree of differential regulation. We iden-
tified over 5,000 proteins in each experimental group as well as
the control group. Homeostatic scaling did not alter the absolute
number of distinct newly synthesized proteins, but rather re-
sulted in differences in which proteins were synthesized and to
what degree. We detected 300 proteins that exhibited signifi-
cantly altered protein synthesis as a result of the global activity
manipulations that induce homeostatic scaling. Recently, other
groups have combined BONCAT with SILAC in order to include
an additional validation step for new protein synthesis and
to enable isotope-based, robust quantification (Bagert et al.,
2014; Eichelbaum and Krijgsveld, 2014). Here we circumvented
the need for SILAC, applying stringent control experiments and
analyses and a highly stable LC-MS/MS setup, producing the
largest dataset for the newly synthesized neuronal proteomes
to date. We also investigated ‘‘low-abundance’’ proteins that
are notoriously challenging to quantify due to the limited number
of detectable peptides or low peptide intensities. We employed
a combination of reproducibility, spectral counting, and normal-
ized peptide intensities to manually evaluate a subset of
low-abundance proteins, and as such these evaluations are
‘‘semi-quantitative’’; the derived lists represent ‘‘trends’’ that
may be of interest.
The significantly regulated newly synthesized proteins we
identified spanmany functional categories and reside in different
cellular compartments. Because of the time course of the plas-
ticity and the duration of the metabolic labeling (24 hr), these
proteins can represent regulated ‘‘sensors,’’ which respond
to the activity manipulation, or ‘‘effectors,’’ which drive theNeuron 92, 358–371, October 19, 2016 367
implementation of the homeostatic responses. In addition to
these proteins, we explicitly evaluated the previously published
data documenting roles for various proteins in homeostatic
scaling (Table S5). Of the 29 scaling-related proteins we identi-
fied in the literature, we detected 20 as newly synthesized in
our dataset (69%). Of these 20 proteins, we detected either
a trend for regulation or significant regulation associated with
scaling for 65% percent. We also queried the extent to which
our significantly regulated proteins have been associated with
various neurological diseases and found that a large fraction
(166 genes, 51%) have been implicated in one or more
neurological diseases. An emerging view that incorporates the
profound cumulative understanding that many neurological dis-
eases are associatedwithmutations in hundreds to thousands of
proteins is the notion that a loss of homeostasis at the level of
neural circuits is causal (Ramocki and Zoghbi, 2008). The num-
ber of proteins identified and regulated by homeostatic scaling
here provides a starting point to examine how dysregulation of
these ‘‘homeostatic’’ proteins contributes to a variety of neuronal
disorders.
Are the two forms of plasticity, homeostatic up-scaling and
down-scaling, on a single mechanistic continuum, or are orthog-
onal mechanisms used? Most mechanistic studies have focused
onup-scaling, examining the roleofmolecules that areassociated
with AMPA receptor trafficking or stabilization. A general question
is whether the samemechanisms run in reverse for down-scaling.
We observed multiple protein families and regulatory pathways
that exhibited opposite regulation depending on the sign of the
scaling (Figures 4 and S3), suggesting that these two forms of
plasticity can be mediated by differential regulation of a common
molecular-protein continuum. These protein families include, for
example, the ionotropic glutamate receptor complex, proteins
associated with neurotransmitter transport and exocytosis, and
transcription factors. These data support the idea that at least
some of the opposite phenotypes elicited by up- and down-
scaling are driven mechanistically by an overlapping cast of
molecular players, regulated in different directions. If the global
manipulations of activity used here and in other studies possess
a common sensor (e.g., Ca2+), then the downstreammechanisms
that bring about scaling-up or scaling-down could activate Ca2+
sensors with different sensitivities (e.g., Sutton et al., 2007) to
bring about a concerted protein synthesis response.
A central question for all forms of cellular plasticity, of course,
is the degree to which phenotypic changes are driven by
changes in transcription and/or translation. A previous study
indicated a requirement for transcription in homeostatic up-
scaling (Ibata et al., 2008). Here we show for the first time that
inhibition of protein synthesis during the initial 12 hr of scaling
induction blocks both scaling-up and scaling-down. The period
of protein synthesis inhibition was brief relative to the half-life
of most neuronal/synaptic proteins (median = 3.5 days; Cohen
et al., 2013), and there was no effect on baseline mEPSC fre-
quency or amplitude. We thus conclude that the observed
inhibition of scaling reflects a specific requirement for newly
synthesized proteins in the expression of homeostatic scaling.
Whether the observed changes in protein synthesis are due to
changes in translation specifically or accompanied by changes
in transcript level is an interesting question. In our data, there368 Neuron 92, 358–371, October 19, 2016are several examples where multiple elements of a common
signaling cascade are regulated (e.g., Figure 7). An open issue
concerns the transcriptional or translational regulatory mecha-
nisms that coordinate the changes in neuronal compartments
so that elements in the same signaling pathway are consistently
regulated to bring about change at the end-point, e.g., a pos-
itive or negative modulation of synaptic strength. In addition,
although it has not been explicitly addressed here, it is obvious
that the regulated degradation of proteins must also play a role
in sculpting the proteome during homeostatic scaling. Indeed,
we observedmany proteins in the ubiquitin proteasome pathway
that were regulated by scaling (Figure 3C; Table S3).
In addition to the proteomic changes described here, protein
degradation, protein modifications, and/or transient protein
complex formation play critical roles in adjusting synaptic
strength. Indeed, Ehlers (2003) identified a cohort of synaptic
proteins that were differentially regulated by activity manipula-
tions and noted that inhibition of the ubiquitin proteasome
pathway blocked the differential regulation. In addition, fast
adaptions, such as short-term potentiation or depression, often
rely heavily on modifications of existing proteins. In support of
this idea, ‘‘kinases/phosphatases’’ represent the largest differ-
entially regulated group in our dataset (Figure 3C; Table S3).
For example, we found multiple MAP kinases and associated
proteins (Table S3) that play a central role in multiple cellular pro-
cesses. Also, our String analysis revealed that the tyrosine-pro-
tein kinases Lyn and Fyn represent central interaction ‘‘hubs’’ of
the differentially regulated proteins in our dataset. Accordingly,
future studies have to focus on obtaining complementary data
on post-translational modifications and transient complex for-
mation during homeostatic scaling.
We used BONCAT in hippocampal cultures to discover the
nascent proteomic response to both up- and down-scaling. As
the non-canonical amino acid AHA can be charged by the
wild-type MetRS, all cells present in the culture can, in theory,
contribute to the newly synthesized proteins we analyzed. Using
bioinformatics, we were able to approximate attributions of
some proteins to glia or interneurons, but this type of analysis
is clearly limited. For example, it has been shown that homeo-
static scaling can also be elicited at inhibitory synapses (Hart-
man et al., 2006). As such, common proteins in excitatory and
inhibitory neurons that exhibit regulation in opposite directions
might ‘‘cancel each other out’’ and hence not be detected as
significantly regulated in our study. To gain selective access to
particular cell classes, a recent development in which a mutant
MetRS enables cell-type-specific labeling could be used in
future experiments. This has already been employed in both
C. elegans (Yuet et al., 2015) and Drosophila (Erdmann et al.,
2015) to monitor protein synthesis in specific cell types. Applying
this technology to homeostatic scaling and other forms of plas-
ticity will allow us to discern the coordinated proteomic response
in the different cell types that make up neuronal circuits.EXPERIMENTAL PROCEDURES
Preparation and Maintenance of Cultured Neurons
Dissociated hippocampal neurons were prepared and maintained as previ-
ously described (Aakalu et al., 2001). Briefly, hippocampi from postnatal day
0–2 rat pups (strain Sprague-Dawley) were dissected out and dissociated by
either trypsin or papain and plated at a density of 40,000 cells/cm2 onto
poly-D-lysine-coated glass-bottomPetri dishes (MatTek). Cultures weremain-
tained in Neurobasal A medium containing B-27 and Glutamax supplements
(Invitrogen) at 37C for 21 days before experiments commenced. All experi-
ments were carried out with the approval of the German animal experiment
authorities.
Electrophysiology
Whole-cell recordings were performed in hippocampal culture neurons
(DIV 21–27, 40 K cell density) held at70mV in voltage clampmode. To induce
homeostatic plasticity, neurons were pretreated with either bicuculline (40 mM)
or TTX (2 mM) for 24 hr. To block protein synthesis, neurons were incubated in
anisomycin (40mM) for the first 12 hr of the treatment. mEPSCswere recorded
for at least 10 min in extracellular solution containing 140 mMNaCl, 3 mMKCl,
10 mM HEPES, 2 mM CaCl2, 1 mM MgSO4, 15 mM glucose, 2 mM TTX, and
40 mMbicuculline (pH 7.4). Recording pipettes (resistances 3–8MU) contained
120 mM potassium gluconate, 20 mM KCl, 10 mM HEPES, 2 mM MgCl2,
0.1 mM EGTA, 2 mM Na2-ATP, and 0.4 mM Na2-GTP (300 mOsm/L,
pH 7.2). Data were analyzed offline in MATLAB using a custom-made tem-
plate-matching algorithm. Selected mEPSC events were individually screened
with an amplitude threshold of > 5 pA and an exponential decay. Statistics
were conducted using unpaired t tests.
Sample Preparation and MS Analyses
Dissociated hippocampal neurons (DIV 21, two dishes per condition,
800,000 cells in total) were incubated with 4 mM AHA (or methionine for
the control group) and treated with bicuculline (20 mM) or tetrodotoxin (1 mM)
for 24 hr. After incubation, the cells were washed with cold DPBS containing
protease inhibitor cocktails (cOmplete EDTA-free, Roche), harvested, snap-
frozen in liquid nitrogen, and stored at 80C until purification.
For cell lysis, the samples (cell pellets) were centrifuged briefly, the pellets
resuspended in lysis buffer (100 mL, 8 M urea, 200 mM Tris [pH 8.4], 4%
CHAPS, 1 M NaCl, cOmplete EDTA-free protease inhibitor), and lysed using
a pistil. After sonication (4 3 30 s at 4C), benzonase (1 mL of a R 250
units/mL stock solution) was added to the solubilized samples, incubated for
5 min, and centrifuged for 5 min at 10,0003 g. The supernatants (200 mL)
were subsequently incubated with freshly prepared catalyst solution
(250 mL) and Alkyne-Sepharose slurry (50 mL; see manufacturer’s protocol,
Thermo Fisher Scientific) and incubated for 19 hr in the dark under gentle
agitation.
After a short centrifugation (2 min, 1,0003 g), the beads were washed twice
(900 mL each) and incubated with SDS wash buffer (100 mM Tris [pH 8], 1%
SDS, 250 mMNaCl, 5 mM EDTA) containing 10 mM TCEP (250 mL). After incu-
bation for 45 min at 55C under gentle agitation, the samples were centrifuged
for 5 min at 1,0003 g and the supernatants discarded. Each sample was then
incubated with 250 mL SDS wash buffer containing a final concentration of
95mM iodoacetamide for 30min at room temperature in the dark under gentle
agitation.
The samples were then transferred into pre-washed (400 mL H2O, LC-MS/
MS-ChromaSolv; 400 mL SDS wash buffer) Pierce Spin columns and washed
with 20 mL SDS wash buffer, 20 mL 8 M urea in 100 mM Tris (pH 8), and 20 mL
20% (v/v) acetonitrile/water.
After washing, 250 mL of digestion buffer (100 mM Tris, 2 mM CaCl2, 10%
acetonitrile) was added to each column and the resin transferred to an Eppen-
dorf tube. After one washing step with digestion buffer,0.65 mg of EndoLysC
was added to each tube and incubated overnight (22 hr) at 37C with con-
stant agitation. For the second digestion step, each sample was incubated
with 0.65 mg trypsin at 37C overnight (22 hr) with constant agitation.
The proteolytic peptides were extracted by incubating the resin with 500 mL
H2O (0.1% TFA), centrifuging for 5 min at 1,0003 g, and collecting the super-
natant. This stepwas repeated, and the combined supernatants were desalted
using c18-SepPak columns (Waters Corp.). The SepPak resin was washedwith
2 mL of 50% acetonitrile/water (5% acetic acid) and equilibrated using 2 mL
water (0.1% TFA). Each sample (1 mL) was loaded onto a column and
washed with 2 mL of water (0.1% TFA) and 200 mL of water (0.5% acetic
acid). Peptides were eluted using 0.5 mL of 50% acetonitrile/water (0.5%acetic acid), dried using a Speed-Vac, and stored at 80C until LC-MS/MS
analysis.
For LC-MS/MS injection, the dried peptide fractions were dissolved in 5%
acetonitrile with 0.1% formic acid, and subsequently loaded using a nano-
HPLC (Dionex U3000 RSLCnano) on reverse-phase columns (trapping col-
umn: particle size 3 mm, C18, L = 20 mm; analytical column: particle size <
2 mm, C18, L = 50 cm; PepMap, Dionex/Thermo Fisher Scientific). Peptides
were eluted in gradients of water (buffer A: water with 5% [v/v] acetonitrile
and 0.1% formic acid) and acetonitrile (buffer B: 20% [v/v] water, 80% [v/v]
acetonitrile, and 0.1% formic acid). All LC-MS/MS-grade solvents were pur-
chased from Fluka. Gradients were ramped from 4% to 48% B in 178 min at
flowrates of 300 nL/min. Peptides eluting from the column were ionized online
using a Thermo nanoFlex ESI source and analyzed in a Thermo ‘‘Q Exactive
Plus’’ mass spectrometer. Mass spectra were acquired over the mass range
350–1,400 m/z, and sequence information was acquired by computer-
controlled, data-dependent automated switching to MS/MS mode using
collision energies based on mass and charge state of the candidate ions
(TOP12, MS resolution 70 k, MS2 resolution 35 k, injection time: 120 ms, full
parameter set in Table S9). All samples were measured in quadruplicate
LC-MS/MS runs.
Bioinformatic Processing and Criteria
Raw data were loaded into MaxQuant (version 1.5.3.8; Cox and Mann, 2008)
and analyzed with a customized Andromeda LFQ parameter set (see Table
S9). In brief, spectra were matched to a Rattus norvegicus database down-
loaded from uniprot.org (34,170 entries, reviewed and non-reviewed) and a
contaminant and decoy database. Precursor mass tolerance was set to
20 ppm, fragment ion tolerance to 4.5 ppm, with fixed modification of Cys res-
idues (carboxyamidomethylation +57.021) and variable modifications of Met
residues (Ox +15.995), Lys residues (Acetyl +42.011), Asn and Gln residues
(Deamidation +0.984), and N termini (carbamylation +43.006). Peptide identi-
fications were calculated with FDR = 0.01, and proteins with one peptide per
protein were included for subsequent analyses.
Five independent biological replicates were processed for each group
(methionine control, untreated cells, bicuculline-treated cells, tetrodotoxin-
treated cells). After subtraction of background proteins, protein lists for each
group were compiled containing proteins identified in at least 2 out of 5 repli-
cates. The methionine content of our AHA-labeled proteins was not different
compared to a global proteome (Rattus norvegicus, Uniprot database) as,
on average, 2.38 and 2.40 met residues are present per 100 amino acids,
respectively.
For full details on the data processing, please see Supplemental Experi-
mental Procedures.
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